Valuation: Seres Therapeutics, Inc.

Market Cap 48.08M 42.23M 39.27M 36.04M 67.71M 4.63B 68.76M 466M 182M 2.28B 180M 177M 7.87B P/E 2026 *
-0.66x
P/E 2027 * -0.76x
Enterprise Value 48.08M 42.23M 39.27M 36.04M 67.71M 4.63B 68.76M 466M 182M 2.28B 180M 177M 7.87B EV / Sales 2026 *
3.74x
EV / Sales 2027 * 134x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-5.07%
1 week-6.85%
Current month-37.07%
1 month-29.87%
3 months-38.70%
6 months-68.23%
Current year-66.63%
1 week 4.92
Extreme 4.92
5.44
1 month 4.92
Extreme 4.92
8.25
Current year 4.92
Extreme 4.92
16.42
1 year 4.92
Extreme 4.92
29.98
3 years 4.92
Extreme 4.92
105.8
5 years 4.92
Extreme 4.92
233.8
10 years 4.92
Extreme 4.92
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

Chairperson

25,000 0.2582%
08/07/26 Free

Director

6,500 0.0671%
08/07/26 Free

Director

6,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-5.07%-6.85%-65.83%-94.45% 48.08M
+0.93%+6.97%+59.60%+69.78% 57.28B
-1.92%+6.03%+40.64%+80.66% 54.99B
-0.46%-1.29%+2.86%+425.15% 23.18B
-2.97%-2.35%-22.53%-15.34% 22.59B
-0.66%+1.52%+21.38%-7.30% 20.46B
-1.34%+0.51%+26.03%-28.68% 17.56B
0.00%+1.98%+34.55%+546.54% 15.67B
-1.30%-5.02%+170.77%+310.94% 14.46B
-0.50%-0.98%+21.43%+179.36% 13.92B
Average -1.33%+0.46%+28.89%+146.67% 24.01B
Weighted average by Cap. -0.80%+2.09%+39.17%+136.73%

Financials

2026 *2027 *
Net sales 12.86M 11.29M 10.5M 9.64M 18.11M 1.24B 18.39M 125M 48.72M 609M 48.27M 47.23M 2.1B 358K 314K 292K 268K 504K 34.48M 512K 3.47M 1.36M 16.95M 1.34M 1.31M 58.6M
Net income -70.97M -62.33M -57.97M -53.19M -99.94M -6.83B -101M -688M -269M -3.36B -266M -261M -11.62B -99.82M -87.67M -81.54M -74.82M -141M -9.61B -143M -968M -378M -4.73B -375M -367M -16.34B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
24/07/26 US$4.965 -5.07% 84,528
23/07/26 US$5.230 -0.95% 29,816
22/07/26 US$5.280 +0.57% 28,772
21/07/26 US$5.250 +2.74% 26,940
20/07/26 US$5.110 -4.13% 48,944
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.965USD
Average target price
17.00USD
Spread / Average Target
+242.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock